Nuclear mRNA quality control in yeast is mediated by Nrd1 co-transcriptional recruitment, as revealed by the targeting of Rho-induced aberrant transcripts by Honorine, Romy et al.
Nuclear mRNA quality control in yeast is mediated
by Nrd1 co-transcriptional recruitment, as revealed
by the targeting of Rho-induced aberrant transcripts
Romy Honorine
1, Christine Mosrin-Huaman
1, Nade `ge Hervouet-Coste
1, Domenico Libri
2
and A. Rachid Rahmouni
1,*
1Centre de Biophysique Mole ´culaire, UPR 4301 du CNRS, Rue Charles Sadron, 45071 Orle ´ans and
2Centre de Ge ´ne ´tique Mole ´culaire, FRE 3144 du CNRS, Avenue de la Terrasse, 91190 Gif sur Yvette, France
Received September 3, 2010; Revised November 4, 2010; Accepted November 5, 2010
ABSTRACT
The production of mature export-competent tran-
scripts is under the surveillance of quality control
steps where aberrant mRNP molecules resulting
from inappropriate or inefficient processing and
packaging reactions are subject to exosome-
mediated degradation. Previously, we have shown
that the heterologous expression of bacterial Rho
factor in yeast interferes in normal mRNP biogen-
esis leading to the production of full-length yet
aberrant transcripts that are degraded by the
nuclear exosome with ensuing growth defect.
Here, we took advantage of this new tool to inves-
tigate the molecular mechanisms by which an
integrated system recognizes aberrancies at each
step of mRNP biogenesis and targets the defective
molecules for destruction. We show that the target-
ing and degradation of Rho-induced aberrant
transcripts is associated with a large increase of
Nrd1 recruitment to the transcription complex
via its CID and RRM domains and a concomitant
enrichment of exosome component Rrp6 associ-
ation. The targeting and degradation of the
aberrant transcripts is suppressed by the overpro-
duction of Pcf11 or its isolated CID domain, through
a competition with Nrd1 for recruitment by the
transcription complex. Altogether, our results
support a model in which a stimulation of Nrd1
co-transcriptional recruitment coordinates the rec-
ognition and removal of aberrant transcripts by
promoting the attachment of the nuclear mRNA
degradation machinery.
INTRODUCTION
During transcription elongation in the eukaryotic nu-
cleus, the nascent mRNA molecule is sequentially coated
with a variety of processing and binding proteins that
mediate its transformation into an export-competent
ribonucleoprotein particle (mRNP) ready for translation
in the cytoplasm (1,2). The co-transcriptional maturation
and assembly of export-competent mRNPs is facilitated
by the C-terminal domain (CTD) of the largest subunit
of RNA polymerase II (RNAP II) that serves as a
platform for sequential recruitment of the various
factors (3). The CTD is formed by a tandem repetition
of a heptapeptide motif (Tyr1–Ser2–Pro3–Thr4–Ser5–
Pro6–Ser7) where a dynamic phosphorylation and
dephosphorylation of Ser5 and Ser2 over the course of
gene transcription adjusts the sequential recruitment of
acting factors (4–7).
The production of export-competent transcripts is also
under the surveillance of quality control steps that are
interconnected with transcription elongation and mRNP
biogenesis. Aberrant mRNP molecules resulting from in-
appropriate or inefﬁcient processing and packaging reac-
tions are targeted by the surveillance mechanisms leading
to their retention at the transcription sites where they are
degraded by the 30–50 exonuclease activity of the nuclear
exosome (8–11). Insights into this process have come from
studies of the budding yeast Saccharomyces cerevisiae
mutant strains with defects in mRNA 30-end formation
or mRNP assembly and export machineries (12–15). It
was shown that deletion or mutation of some components
of the THO/Sub2 complex, which loads onto the nascent
transcript and connects transcription to export, leads to a
decrease in steady-state levels of several mRNAs. The
normal levels of mRNAs can be recovered by inactivation
of the nucleus-speciﬁc exosome component Rrp6 or
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(16,17). This Rrp6-dependent loss of mRNAs is also
observed in strains carrying mutations in the mRNA
30-end processing factors Rna14 and Rna15 (14,18).
The molecular mechanisms by which an integrated
system recognizes aberrancies at each step of mRNP bio-
genesis and targets the defective molecules for destruction
are still largely unknown. However, several lines of
evidence point to a model in which the surveillance appar-
atus is recruited directly to the transcription complex, a
position from which it can scrutinize all mRNP processing
and packaging reactions looking for faulty events. For
instance, components of Drosophila nuclear exosome
have been shown to accompany transcribing RNAP II
upon recruitment by transcription elongation factors
(19,20). In yeast, genome-wide analyses indicated
that the localization of some nuclear exosome subunits
correlates with actively transcribed genes (21). Also,
co-immunoprecipitation experiments in yeast suggested
that components of both the exosome and TRAMP
interact physically with the transcription complex. This
interaction seems to be mediated by Nrd1, a protein
involved in transcription termination of a subset of
RNAs (22).
Two main pathways of terminating RNAP
II-dependent transcripts have been described in yeast.
Termination of poly(A)-containing mRNAs relies on the
co-transcriptional recruitment and assembly of a large
cleavage and polyadenylation complex that recognizes
the termination signal and triggers the cleavage of the
nascent transcript with subsequent addition of a poly(A)
tail at the 30-end (23–27). The highly conserved factor,
Pcf11, is a prominent component of this complex that
interacts with RNA as well as RNAP II via a
CTD-interacting domain (CID) (28–32). The second ter-
mination pathway, used by RNAP II in transcription of
the non-coding snRNAs and snoRNAs, is directed by
another CID-containing protein, Nrd1, which binds
RNA in a sequence-speciﬁc manner (33–35). Nrd1 is re-
cruited to the transcription complex in association with
another sequence-speciﬁc RNA binding protein, Nab3.
Recently, the Nrd1–Nab3 complex was also implicated
in termination and fast decay of cryptic unstable tran-
scripts (CUTs); short non-coding RNAs that were ﬁrst
detected by genome-wide microarray analyses in strains
defective for nuclear RNA degradation (36–38). Current
models suggest that the co-transcriptional loading of
Nrd1–Nab3 complex mediates the recruitment of the
exosome and TRAMP which in the case of snRNAs and
snoRNAs couples termination to maturation by trimming
the 30-ends of precursor RNAs until the encounter of a
block formed by stable RNA structures or RNA-bound
Nrd1–Nab3 (22,34). It was also suggested that the absence
of such structural features in the case of the short-lived
CUTs leads to their complete degradation following ter-
mination (36,37).
Recent studies ascribed the choice between the two ter-
mination modes to the stage of CTD phosphorylation
which is dependent on the distance traveled by RNAP II
from the promoter. Termination of short transcripts
(non-coding RNAs and CUTs) appears to be associated
with Ser5 phosphorylation and preferential recruitment of
Nrd1 (39,40), whereas termination of longer transcripts
relies on the subsequent phosphorylation at Ser2 sites
that mediates recruitment of Pcf11 (23,41). However,
chromatin immunoprecipitation (ChIP) experiments
show clearly that Nrd1 cross-linking is not limited to the
early transcribed region of a gene. Nrd1 recruitment
within the body of the gene and at its 30-end is only
slightly decreased as compared to the 50 part (23,40).
Furthermore, a recent reevaluation indicates that the
level of Ser5 phosphorylation, necessary for Nrd1 recruit-
ment, persists throughout elongation (42,43). These results
suggest that Nrd1 could play a pivotal role in the mRNP
surveillance mechanism as a part of a protein network that
travels with the transcription complex along the transcrip-
tion unit.
Previously, we have implemented an assay in which
mRNP biogenesis in yeast is disturbed by the heterologous
expression of the bacterial transcription termination
factor Rho. The expression of this RNA-dependent
helicase/translocase induces the production of full-length
yet aberrant transcripts that are targeted by the surveil-
lance mechanism leading to their destruction by the
nuclear exosome (44). Here, we took advantage of this
new assay to explore the involvement of Nrd1 in the
nuclear quality control system. We show that Nrd1 re-
cruitment by the transcription complex via its CID and
RRM domains is required for the targeting and degrad-
ation of the Rho-induced defective transcripts.
Remarkably, overexpression of Pcf11 or its isolated CID
domain suppresses the targeting and degradation of the
Rho-induced aberrant transcripts through a competition
with Nrd1 for recruitment by the transcription complex.
Altogether, our results provide genetic and molecular
evidence indicating that the recognition and targeting of
aberrant transcripts is mediated by a large increase in
Nrd1 recruitment to the transcription complex which
helps to tether the nuclear mRNA degradation machinery.
MATERIALS AND METHODS
Yeast strains and plasmids
The yeast strains used in this study are listed in
Supplementary Table S1. Similarly, all the plasmids are
listed in Supplementary Table S2. The various
overexpression plasmids with N- and C-terminal trunca-
tions in the PCF11 and NRD1 genes were constructed by
ampliﬁcation of genomic DNA with the gateway primers
described in Supplementary Table S3. The M1, M2 and
M3 mutations in pcf11-(1–145) were introduced by
overlapping PCR mutagenesis with the primers described
in Supplementary Table S3. The deletion of the
Nrd1-RRM domain was done by PCR with two sets of
partially overlapping primers designed to amplify the
DNA sequence corresponding either to the ﬁrst 339
amino acids or the last 165 amino acids of the Nrd1
protein. The two PCR products were re-ampliﬁed with
the 50- and 30-end ‘NRD1’ gateway primers described in
Supplementary Table S3 to create the RRM plasmid.
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Yeast cells transformed with the appropriate plasmids
were grown at 25 Ct oa nO D 600 of 0.6, then total
RNAs were extracted by the hot phenol method (45).
Northern blot and hybridization were described previous-
ly (44). Formaldehyde-containing 1.2% agarose gel was
used to analyze PMA1 and PGK1 mRNAs and the 5.8S
or 18S rRNAs which were detected sequentially using
either a PMA1 random-primed probe or 50-end labeled
probes (see Supplementary Table S4). Hybridization
signals were quantiﬁed with a Storm 860 phosphorimager
(Molecular Dynamics) and the data were processed with
Imagequant software version 2005.
Chromatin immunoprecipitation
Preparations of chromatin were performed essentially as
described by (46). The NRD1-TAP (DLY1124) or RRP6-
TAP (DLY269) strains were co-transformed with the
empty vector (pCM185) or the Rho expression plasmid
(pCM185-Rho) and either the pAG425GPD vector, the
Nrd1 (1–448) or the Pcf11 (1–300) constructs. The ‘no
TAG’ control strain is W303 transformed with
pAG425GPD vector and either the pCM185 or the
pCM185-Rho plasmids. Two hundred millilitre of cells
grown for  20h without doxycycline (OD600   0.6)
were ﬁxed with 1% formaldehyde for 20min. After
glycine addition to stop the reaction, the cells were
washed and lysed with glass beads to isolate chromatin.
The cross-linked chromatin was sheared by sonication to
reduce average fragment size to  500bp. Immuno-
precipitation of 800ml of chromatin fractions was per-
formed with 37ml of IgG sepharose (GE healthcare)
overnight at 4 C. After washing beads and chromatin
elution, the eluted supernatants and the input controls
were incubated with pronase (Sigma, 0.8mg/ml ﬁnal con-
centration) for 1h at 37 C followed by 5h at 65 Ct o
reverse cross-linked DNA complexes. DNA was extracted
using the Qiagen PCR-clean up columns. The immunopre-
cipitated DNAs (output) were quantitated by real time
PCR (LightCycler 480 from Roche with the products
and instructions recommended by the supplier) using
three sets of primers located along the PMA1 or PGK1
coding sequence (described in Supplementary Table S5)
and normalized to a 1/200 dilution of input DNA.
Ampliﬁcations were done in duplicate for each sample,
averages and standard deviations were calculated based
on three independent experiments.
RESULTS
Bacterial Rho factor induces the production of aberrant
transcripts in yeast
In a recent study (44), we reported that the conditional
expression of the bacterial Rho factor in the yeast nucleus
leads to a dose-dependent growth defect phenotype that
stems from its interference in mRNP biogenesis. Rho
helicase/translocase action induces the production of
full-length but aberrant transcripts that are targeted and
degraded by the nuclear exosome. This effect is illustrated
in Figure 1 where the growth of yeast cells expressing Rho
under the control of a Doxy-regulated TetO7 promoter
within a centromeric plasmid is severely reduced under
inducing conditions (-Doxy). Northern blot analysis of
the steady-state abundance of a representative mRNA
(PMA1) shows almost complete disappearance of the
transcript under Rho expression conditions (Figure 1B).
However, in a strain lacking the nuclear exosome compo-
nent Rrp6, the Rho-induced growth defect is totally
relieved (Figure 1A) and the steady-state abundance of
PMA1 mRNA is now only slightly affected by Rho ex-
pression (Figure 1B), indicating that Rho action leads to
the production of full length yet defective mRNPs that
had been eliminated in the presence of active nuclear
RNA degradation machinery. This conclusion was sup-
ported also by examination of the PMA1 mRNA 30-ends
following RNase H cleavage (44). The rescue of PMA1
mRNA was also obtained upon depletion of two compo-
nents of the TRAMP complex, Air1 and Air2 [results not
shown and (44)]. A similar trend was observed when the
steady-state level of another mRNA (PGK1) was moni-
tored (Figure 1B). Note, however, that the effect of Rho
on PGK1 expression is less pronounced than for PMA1,
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Figure 1. Depletion of the exosome component Rrp6 alleviates
Rho-induced growth defect and restores the steady-state levels of
mRNAs. (A) The rrp6D mutant and the corresponding wild-type
isogenic strain (RRP6) were transformed with the empty vector
(pCM185) or the Rho-expression construct harboring the Rho gene
under the control of a Doxy-regulated TetO7 promoter
(pCM185-Rho). Ten-fold serial dilutions of transformants grown select-
ively in liquid medium at 25 C with 1mg/ml Doxy (non-induced con-
ditions) were spotted on Rho-repressing (+Doxy) or Rho-inducing
( Doxy) plates. The plates were photographed after 3 days at 25 C.
(B) Northern blot analyses of total RNAs extracted from cultures of
cells transformed with the Rho-expression plasmid and grown with
Doxy at a concentration of 1mg/ml ( Rho) or 0.02mg/ml (+Rho).
Samples of total RNAs (12mg) were fractionated on agarose gel,
transferred to a membrane and the steady-state levels of speciﬁc
RNAs were detected sequentially using a PMA1 random-primed
probe or 50-end labeled probes against PGK1 mRNA and 5.8S
rRNA which serves as loading control (see Supplemental Table S4).
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difference is still unclear, but it could be linked to the
efﬁciency by which Rho loads onto the nascent
transcripts.
Our previous genetic and molecular analyses provided
indirect evidence implying that the loading of Rho onto
nascent transcripts and its subsequent translocation along
the RNA chains counteract the deposition of the endogen-
ous processing and packaging factors. This interference
causes the production of mRNPs that are improperly pro-
cessed or depleted of some crucial proteins and which will
be recognized as export-incompetent and eliminated by
the exosome-mediated nuclear quality control system.
This conclusion led us to screen a yeast genomic library
searching for dosage suppressors of the Rho-induced
growth defect, with the idea that the overproduction of
a protein partner important for mRNP integrity could
shift its competition with Rho and thus rescue the tran-
script from degradation with the ensuing relief of the
growth defect. The rational of this Rho-based screen
was validated by the identiﬁcation of numerous
dosage-suppressor genes that encode proteins involved
in mRNA 30-end formation or mRNP assembly and
export (44).
The suppression of Rho-induced defect by Pcf11
overproduction is mediated by its CID
Among the dosage suppressors found in the Rho-based
screen, Pcf11 is a prominent component of the cleavage
factor CF1A that is recruited to the nascent transcript
through the interaction of its well characterized CID
with the CTD of RNAP II (28,29,31). To gain more
insights into the mechanism by which the overproduction
of Pcf11 suppresses the Rho-induced defect, we con-
structed a set of deletion mutants based on the known
domain organization of the protein [Figure 2A and
(29,31)]. The constructs expressed from a 2m vector were
transformed into yeast cells harboring the Doxy-regulated
Rho expression system and yeast growth was monitored
by serial dilutions on agar plates. Remarkably, the sup-
pressing effect of the Pcf11 variants increased signiﬁcantly
as the C-terminal part of the protein was gradually
trimmed (Figure 2B). The best suppressing phenotype
was obtained with a protein fragment containing the 145
N-terminal amino acids corresponding to the CID domain
of Pcf11. A construct with a further truncation into the
CID domain up to the last 125 N-terminal amino acids
failed to suppress the Rho-induced growth defect. A
similar failure to suppress the Rho-induced defect was
also observed with the deletion variant in which only the
CID domain was removed from Pcf11 (CID). The lack
of suppression is not due to instability of the
overproduced protein fragments as was veriﬁed by
Western blot analyses (see representative examples in
Supplementary Figure S1). These growth results were
substantiated by northern blot analyses showing a correl-
ation between a partial rescue of the steady-state abun-
dance of PMA1 mRNA and the growth defect suppression
(Figure 2C). A similar trend was also observed when the
steady-state level of another mRNA (PGK1) was
monitored (Figure 2C). Taken together, these results
indicate that Pcf11 is a dosage suppressor of the
Rho-induced defect owing to the presence of its CID
domain which is sufﬁcient on its own to abrogate the
defect. Moreover, the fact that the CID fragment is a
better suppressor than full-length Pcf11 suggests that the
dosage-suppression process is mediated by saturable
physical interaction with the CTD. In effect, this inter-
action has been shown by two-hybrid experiments to be
stronger when the CID is in isolation (31).
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Figure 2. Overexpression of the CID of Pcf11 is sufﬁcient to suppress
Rho-induced defect. (A) Schematic representation of the structural
motifs of Pcf11. This diagram indicates the CID, the Q-rich segment
(Q20), the Rna14/Rna15 and Clp1 interaction domains, and the two
zinc-ﬁnger motifs. The numbers correspond to the amino acid
sequence of Pcf11 and the black horizontal lines represent the protein
fragments that were expressed from the 2m plasmid. (B) The two
control strains were done by co-transformation of the 2m plasmid
with either the empty vector (w/o Rho) or the plasmid expressing
Rho into the BMA41 wild-type strain. BMA41 harboring the Rho
expression vector was co-transformed with a 2m plasmid
overexpressing the full-length Pcf11 (FL) or the various deletion
variants represented in A. Strains grown selectively under repressing
conditions were spotted for growth as described in Figure 1A.
(C) Northern blot analyses were made as in Figure 1B and the
membrane was hybridized sequentially with a PMA1 random-primed
probe or 50-end labeled oligonucleotides for PGK1 mRNA and 18S
rRNA which serves as loading control.
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are required for dosage suppression of Rho-induced defect
The ability of the isolated CID of Pcf11 to suppress the
Rho-induced defect on its own led us to focus our inves-
tigations on this protein fragment (constructs 1–145).
Amino acid mutations within a highly conserved region
of the CID (between positions 66 and 70; Figure 3A) that
impair correct transcript termination by Pcf11 have been
characterized in vivo (31). These mutations were also
studied in vitro in isolated CID to deﬁne their relative
contributions to the interactions with the CTD and
RNA (32). The CID-M3 mutant which has three consecu-
tive amino acids substituted by alanines (D68A, S69A and
I70A) lacks both CTD and RNA binding activities. The
CID-M2 variant (D68A, S69A) has a slightly reduced
CTD binding ability but retains full RNA binding
activity. The third mutant, CID-M1 (A66D), has a full
ability to interact with CTD but lacks RNA binding
capacity. The constructs overproducing the CID variants
were transformed into yeast cells harboring the Rho ex-
pression system and growth was monitored by serial dilu-
tions on agar plates. As shown in Figure 3B, both M1 and
M3 mutants have lost the ability to suppress the
Rho-induced growth defect, whereas the M2 variant has
a similar suppressing phenotype than the wild-type CID.
The northern blot analyses are consistent with the growth
results with a signiﬁcant restoration of PMA1 mRNA
abundance in the case of M2 overproduction as
compared to M1 and M3 (Figure 3C). These results
indicate that the relief of Rho-induced defect by
overexpression of the CID domain of Pcf11 requires
both CTD and RNA binding activities of the protein
fragment. However, the lack of RNA binding activity
seems to be critical for the suppressing process.
The Rho-induced defect is aggravated in yeast cells with
defective Pcf11
The results described above suggest that the suppression
of Rho-induced defect by overproduction of Pcf11 or its
CID domain could be mediated by a competition with a
factor recruited to the transcription complex that orches-
trates the targeting of aberrant transcripts with the
ensuing growth defect. If such competition is already
taking place under physiological expression of Pcf11,
then a deﬁciency in its CID that impairs its CTD and
RNA binding activities should exacerbate the
Rho-induced defect. To evaluate this assumption, we
tested the sensitivity to Rho expression of the yeast
mutant strain pcf11–13 which has a defect in the CID of
Pcf11 corresponding to the M3 substitutions described
above (31). The sensitivity to the bacterial factor was
monitored by expressing both the wild-type Rho and the
Rho-KE variant which has a point mutation that reduces
its helicase/translocase activity producing a mild growth
defect phenotype in yeast (44). This intermediate effect of
Rho-KE in yeast is particularly convenient to monitor
synergistic sensitivity effects. As shown in Figure 4A, a
similar growth inhibition was observed for PCF11 and
pcf11–13 cells upon expression of wild-type Rho. In
contrast, the expression of Rho-KE, which had virtually
no effect on the growth of wild-type PCF11 cells under the
present conditions, induced a signiﬁcant growth defect for
cells harboring the pcf11–13 allele. This different sensitiv-
ity of the two isogenic strains to Rho-KE expression was
corroborated by northern blot analysis of PMA1 mRNA
where the steady-state level was slightly affected by
Rho-KE expression in pcf11–13 cells as compared to the
wild-type strain (Figure 4B). Western blot analysis indi-
cates that Rho-KE protein is expressed at a similar level in
both strains. We also tested the mutant allele pcf11-2
which is defective in transcript cleavage and
polyadenylation and in which the mutations are located
exclusively outside the CID with no effect on CTD
binding (28,31). In this case, the sensitivity to Rho and
Rho-KE expression was similar to the wild-type strain
(results not shown). These results support the idea that
the recruitment of a factor that mediates the targeting
and degradation of Rho-induced aberrant transcripts is
favored in the presence of Pcf11 having a defective CID.
The Rho-induced defect is suppressed in yeast cells with
defective Nrd1 or Nab3 as well as a shortened CTD
Nrd1 is known to interact both with the CTD through its
CID domain which is homologous to that of Pcf11 (40)
and with RNA by recognizing sequence elements within
M2
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Figure 3. The CTD and RNA binding activities of Pcf11-CID are
required for dosage suppression of the Rho-induced defect.
(A) Schematic representation of the amino acid substitutions introduced
within the CID protein fragment (1–145) of Pcf11. The CTD and RNA
binding abilities of the protein variants as described in ref. (32) are
indicated on the right side. (B) BMA41 strains were co-transformed
with pCM185-Rho and one of the 2m plasmids overproducing the
Pcf11-CID domain variants. Growth tests were carried out as described
in Figure 1A. (C) Northern blots were performed as in Figure 2C.
Nucleic Acids Research,2011, Vol.39, No. 7 2813the nascent transcript in association with Nab3 (33,47).
The Nrd1 complex was also shown to interact with the
exosome and TRAMP (22). These properties led us to
suspect Nrd1 as the possible factor that mediates the tar-
geting and degradation of Rho-induced aberrant tran-
scripts upon its recruitment to the transcription complex.
This hypothesis was also supported by the fact that, in
contrast to Pcf11, Nrd1 was not found as a dosage sup-
pressor in our Rho-based screen and did not suppress the
Rho-induced defect when tested directly following its
cloning and overexpression (see the experiment described
in Figure 7). As a ﬁrst step to examine our prediction, we
tested the sensitivity to Rho expression of a yeast strain
harboring a CID deletion allele of NRD1 (nrd1D1–151).
Previously, the Nrd1CID protein was reported to have
low afﬁnity for binding RNAP II in cell extracts and its
recruitment to two mRNA genes (including PMA1) was
shown by ChIP experiments to be signiﬁcantly reduced
(40). The nrd1D1–151 strain was transformed with the
Rho expression plasmid and the growth was monitored
in parallel with an isogenic wild-type strain as a control.
The transformant spotted on agar plates recovered a
full capacity to grow under Rho-inducing conditions
(Figure 5A). In agreement with the growth results, the
steady-state level of PMA1 mRNA in the presence of
Rho was rescued signiﬁcantly in the nrd1D1–151 mutant
strain (Figure 5B), indicating that Nrd1 recruitment to the
transcription complex is required for the targeting and
degradation of aberrant transcripts generated by Rho
action. This assertion was further veriﬁed by analyzing
the sensitivity to Rho expression of the strain nrd1–102
which has a single-point mutation in the RRM (RNA
recognition motif) of Nrd1 leading to a deﬁciency in
snoRNA termination as a result of a reduced RNA
binding activity (47). Consistently, the Rho-induced
growth defect was readily suppressed by the nrd1–102
mutation with the accompanying rescue of the PMA1
steady-state mRNA level (Figure 5). These results
suggest that both CTD and RNA biding activities of
Nrd1 are required to mediate the targeting and degrad-
ation of Rho-induced aberrant transcripts.
To test further the involvement of the Nrd1 complex in
the targeting and degradation of Rho-induced aberrant
transcripts, we examined the effect of alterations in two
important partners (Nab3 and CTD) that contribute to
Nrd1 recruitment. Nab3 forms a heterodimer with Nrd1
and binds to a speciﬁc RNA motif via its RRM domain
(48). The effect of Rho expression was tested in the nab3–
11 allele which has two point-mutations within the RRM
region (47). As shown in Figure 6, a slight but signiﬁcant
relief of Rho-induced growth defect as well as a corres-
ponding rescue of PMA1 mRNA was observed for the
cells harboring the nab3–11 allele as compared to the
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Figure 4. A Pcf11 mutant strain with a defective CID due to impaired
CTD and RNA binding activities is Rho hypersensitive. (A) The pcf11–
13 mutant (DLY915) and the wild-type isogenic strain (DLY913) were
transformed with an empty vector (pCM189) or a plasmid expressing
Rho (pCM189-Rho) or the Rho-KE variant (pCM189-Rho-KE).
Growth tests were carried out as described in Figure 1A.
(B) Northern blot analyses of total RNAs extracted from the trans-
formed strains expressing (+) or not ( ) the Rho-KE protein variant
were performed as described in Figure 1B. The lower panel (a-Rho)
shows the western blot analysis of Rho-KE expression in wild-type and
pcf11–13 mutant strains with the puriﬁed bacterial Rho protein (shown
at the right side with an asterisk) as a Marker. The proteins were
revealed using custom made anti-Rho polyclonal antibodies
(Eurogentec, Belgium).
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Figure 5. Nrd1 mutant strains with deletion of the CID or mutation in
the RRM are less sensitive to Rho. (A) The two Nrd1 mutant alleles,
nrd1D1–151 (YNH026) and nrd1–102 (DLY1146), and the correspond-
ing wild-type isogenic strains (NHY001 and DLY1144, respectively)
were transformed with the empty vector or the plasmid expressing
Rho. Cell cultures were spotted for growth tests as described in
Figure 1A. (B) Northern blot analyses were performed as in Figure 1B.
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and rescue of PMA1 mRNA were even more pronounced
in a yeast strain in which the CTD of RNAP II was
truncated from 26 (wild-type) to 11 heptapeptide repeats
(Figure 6), emphasizing the importance of the CTD as a
platform for Nrd1 recruitment. Altogether, these results
indicate that alterations in the different factors known to
contribute to the co-transcriptional recruitment of Nrd1
counteract the targeting and degradation of Rho-induced
aberrant transcripts, implying that the nuclear mRNA
surveillance mechanism relies on efﬁcient association of
Nrd1 with the transcription machinery.
The Rho-induced defect is suppressed by overproduction
of Nrd1 deletion mutants but not the full-length protein
If the mRNA surveillance mechanism relies on Nrd1 re-
cruitment to the transcription machinery, then the over-
production of a mutant variant of the protein, that is
functionally defective but still able to be recruited,
should exert a dominant-negative effect by outcompeting
the functional Nrd1 leading to a suppression of the
Rho-induced defect. To test this hypothesis, we con-
structed a set of deletion mutants of Nrd1 based on the
known domain organization [Figure 7A and (47)]. The
constructs made within a high copy number 2m plasmid
were transformed into yeast cells harboring the Rho ex-
pression system. As shown in Figure 7B, the overproduc-
tion of a protein fragment containing the 151 N-terminal
amino acids of Nrd1 corresponding to its CID domain
(constructs 1–151) was unable to suppress the
Rho-induced defect, indicating that additional contacts
are probably needed for efﬁcient competitive recruitment
by the transcription complex. The possibility that the
absence of suppression is due to instability of the
overproduced protein was ruled out by western blot
analysis (see representative examples in Supplementary
Figure S1). The Rho-induced defect was partially
relieved with a longer protein fragment that includes
half of the Nab3-interacting region (constructs 1–178).
The protein fragment encompassing the CID, the
1-151
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Figure 7. Rho-induced defect is alleviated by overexpression of
truncated forms of Nrd1. (A) Schematic representation of the domain
organization of Nrd1. This diagram indicates the CID, the Nab3 inter-
action domain, the arginine–glutamine and arginine–serine rich region
(RE/RS), the RNA recognition motif (RRM) and the proline- and
glutamine-rich region (P/Q), respectively. The numbers correspond to
the amino acid sequence of Nrd1 and the horizontal lines represent the
protein regions which were expressed from the 2m vector. (B) The
control strains were done as in Figure 2. The other strains were
co-transformed with the Rho-expression vector and one of the 2m
plasmids overexpressing the full-length Nrd1 (FL) or a truncated
variant as indicated in (A). Growth tests were carried out as described
in Figure 1A. (C) Northern blot analyses were made as in Figure 1B.
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Figure 6. Cells with a defective Nab3 protein or a truncated CTD
become less sensitive to Rho expression. (A) The nab3–11 mutant
(YPN102), the CTD 11 mutant (rpo21-D104) which lays 11 repetitions
of the heptapeptide and the corresponding W303 wild-type isogenic
strains (NAB3 and CTD 26, respectively) were transformed with the
empty vector or the plasmid expressing Rho. Growth tests were carried
out as described in Figure 1A. (B) Northern blot and hybridization
were performed as in Figure 1B.
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(constructs 1–369) was able to fully suppress the
Rho-induced growth defect. A similar suppressing pheno-
type was observed with the deletion mutant containing the
whole RRM region (constructs 1–448). These results
suggest that Nab3 association with the mutant Nrd1 in-
creases its competing efﬁciency, whereas the presence of
the RRM region appears to be dispensable for an efﬁcient
competition. Consistent with this, the Nrd1 variant
lacking only the RRM region (construct RRM) was
able to compete with functional Nrd1 leading to robust
suppression of the Rho-induced defect. As expected, the
overexpression of Nrd1 protein lacking the CID domain
(Nrd11–151) failed to suppress the Rho-induced defect,
reﬂecting the importance of CTD interactions for the com-
petition process (results not shown). Similarly, the over-
production of the full-length Nrd1 protein did not show
any suppressing phenotype. Indeed, in this case, the
overexpressed plasmid-borne protein outcompetes the en-
dogenous Nrd1 but it is functionally competent to mediate
the targeting and degradation of Rho-induced aberrant
transcripts leading to the growth defect. Northern blot
measurements of the steady-state abundance of PMA1
mRNA and PGK1 mRNA (Figure 7C) corroborated the
growth results. We conclude that Nrd1 recruitment to the
transcription machinery coordinates the recognition and
removal of the Rho-induced aberrant transcripts,
probably by promoting the tethering of the exosome-
mediated degradation apparatus (see below).
Rho expression stimulates the co-transcriptional
recruitment of Nrd1 and Rrp6
Previous chromatin immunoprecipitation (ChIP) experi-
ments have shown Nrd1 cross-linking across the PMA1
gene with a slight enrichment toward the 50 and 30 regions
of the locus (23,40,43). We wanted to see whether Rho
action would lead to an increase of Nrd1 recruitment or
a change in its cross-linking proﬁle. We therefore analyzed
the distribution of TAP-tagged Nrd1 along the PMA1
gene under Rho inducing or repressing conditions and in
the absence or presence of competing suppressors. The
Nrd1 occupancy was assessed by quantitative PCR
(qPCR) using three primer-pairs that cover the 50, the
middle and the 30 regions of the gene (Figure 8A). As
shown in Figure 8B, the ChIP signals in the absence of
Rho are consistent with previous reports (23,40,43) with
occupancy slightly higher in the 50 and 30 regions as
compared to the body of the gene. Remarkably, the ex-
pression of Rho leads to a 4-fold increase of Nrd1 recruit-
ment across the entire locus with a similar enrichment
toward both ends. Moreover, this Rho-induced stimula-
tion of Nrd1 recruitment to the PMA1 gene is attenuated
signiﬁcantly by overexpression of competing suppressors
such as the Nrd1 (1–448) or Pcf11 (1–300) protein frag-
ments (Figure 8B), reﬂecting the competition for inter-
action with the transcription complex. Note, however,
that the attenuation of Rho-induced Nrd1 recruitment
by the competing suppressors is less pronounced for the
50 region as compared to the 30 region or the body of the
gene, which could be linked to the stage of CTD
phosphorylation and/or a more inherently robust recruit-
ment of Nrd1 within the promoter-proximal region.
Additionally, the basal level of Nrd1 occupancy in the
absence of Rho is higher when the Pcf11 suppressor-
derivative is expressed (for both PMA1 and PGK1 loci)
which leads to a less efﬁcient reduction of the effect of
Rho on Nrd1 recruitment. The reason for this behavior is
presently unclear. ChIP experiments conducted in parallel
revealed that Rho expression induces a 15% decrease of
RNAP II cross-linking along the PMA1 locus (results not
shown). This is presumably due to a low level of premature
Rho-dependent termination within promoter-proximal
region, which is consistent with the fact that a fraction of
full length transcripts is still missing upon inactivation of
the degradation machinery [rrp6D in Figure 1 and (44)]. A
similar trend was observed when Nrd1 recruitment across
PMA1 (2757 bp)
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Figure 8. Rho action stimulates Nrd1 and Rrp6 recruitment across
the PMA1 gene. (A) Schematic representation of the PMA1 gene
with the horizontal bars denoting the positions of the PCR products
used in the ChIP analyses. (B) Quantiﬁcations of the fold enrichment
for PMA1 DNA in Nrd1-TAP immunoprecipitates from cells express-
ing Rho (+Rho) or not ( Rho) and co-transformed with either the
empty 2m vector for the assays without suppressor or the plasmids
overexpressing the suppressors Nrd1 (1–448) or Pcf11 (1–300). The
‘no TAG’ control strain is W303 transformed with the empty 2m
vector and either the ( Rho) or the (+Rho) plasmids.
Immunoprecipitated samples (output) were normalized to input. The
average of three independent experiments is shown with error bars
representing standard deviations. (C) Quantiﬁcations of the fold enrich-
ment for PMA1 DNA in Rrp6-TAP immunoprecipitates carried out as
in (B).
2816 Nucleic Acids Research, 2011,Vol.39, No. 7the PGK1 gene was monitored (Supplementary Figure S2).
Again, these results provide a strong support for the in-
volvement of Nrd1 in the targeting of Rho-induced
aberrant transcripts through its association with the tran-
scription machinery.
We next asked whether the anchoring of Nrd1 to the
transcription machinery promotes the association of the
exosome-mediated degradation apparatus. We, therefore,
performed ChIP experiments with a strain harboring
TAP-tagged nuclear-speciﬁc exosome component Rrp6.
As shown in Figure 8C, a large increase of ChIP signals
across the PMA1 locus is observed under Rho-inducing
conditions and this stimulation of Rrp6 recruitment is
also readily reversed by overexpression of a competing-
suppressor such as Nrd1 (1–448) protein fragment.
Clearly, these results highlight a direct link between
Nrd1 and Rrp6 recruitments to the transcription machin-
ery upon Rho action. Interestingly, parallel experiments
using TAP-tagged core exosomal components Rrp4 and
Rrp41 did not show any signiﬁcant ChIP signals both in
the presence and the absence of Rho (results not shown),
suggesting either a loose interaction between the anchored
Rrp6 and the exosome or the possibility that Rrp6 may act
independently from core exosome to target and degrade
aberrant transcripts (see ‘Discussion’ section).
DISCUSSION
Eukaryotic cells have evolved an mRNP quality control
system by which aberrant transcripts with processing and
assembly defects are recognized as export-incompetent
triggering their degradation by the nuclear exosome.
Previous studies have suggested the interconnection of
this surveillance process with transcription elongation
and mRNP biogenesis. However, the molecular mechan-
isms by which a surveillance apparatus recognizes
aberrancies at each step of mRNP formation and targets
the defective molecules for destruction remained
unknown. To address this question, we took advantage
of a new assay in which the heterologous expression of a
bacterial RNA-dependent helicase/translocase (transcrip-
tion termination factor Rho) in yeast induces the produc-
tion of full-length yet aberrant transcripts that are
targeted and degraded by the nuclear exosome, causing
a growth defect phenotype (44). In vitro, Rho functions
as a powerful molecular motor that tracks along the RNA
chain and can melt nucleic acid base pairs or disrupt
RNA–protein complexes present on its path (49–51). We
have postulated that Rho loading and subsequent trans-
location along nascent transcripts in yeast cells could an-
tagonize the normal deposition of processing and
packaging factors, yielding stripped mRNPs that are
recognized as defective. This assumption was supported
by the identiﬁcation of several mRNP processing and
packaging factors in a screen for dosage suppressors of
the Rho-induced defect, suggesting that an overload of
these RNA-interacting proteins can counteract the
denuding effect of the bacterial helicase or neutralize the
detection of the aberrant transcripts by the surveillance
mechanisms. Additional support to our assumption is
provided by a work to be published elsewhere in which
decreased occupancy of some mRNP assembly proteins
upon Rho action was revealed by ChIP experiments
(R. H., C. M., N. C. and A. R. R., manuscript in
preparation).
Among the dosage suppressors found in the Rho-based
screen, Pcf11 is an essential factor for transcription ter-
mination of poly(A)-containing RNAs which is known
to interact with the nascent transcript upon
co-transcriptional recruitment by the CTD of RNAP II
(28–32). These functional features incited us to use the
Pcf11 suppressing ability as a starting point to investigate
the mechanisms by which Rho-induced aberrant tran-
scripts are recognized and targeted for destruction. A sys-
tematic deletion analysis of Pcf11 indicates that the rescue
of Rho-induced aberrant transcripts and the accompany-
ing relief of growth defect by overproduction of the
protein stems from a physical interaction of its CID
domain with the transcription complex. The interaction
requires both CTD and RNA contacts and is more efﬁ-
cient with isolated CID fragment than the full-length
protein. Similar rescue of Rho-induced aberrant tran-
scripts and relief of growth defect were obtained when
endogenous Nrd1, the other CID-containing protein
involved in transcription termination of small non-coding
RNAs, was altered in its CTD and RNA binding deter-
minants by deletion of its CID or mutations within its
RRM. Thus, overproduced Pcf11 or its CID-containing
fragments exert their suppressing effect by outcompeting
Nrd1 for recruitment by the transcription complex.
Consistent with this conclusion, a similar competition-
mediated suppression of Rho-induced defect is achieved
by overproduction of functionally-deﬁcient CID-
containing Nrd1 fragments. Together, these results show
that the recognition and targeting for destruction of
Rho-induced aberrant transcripts is mediated by Nrd1 as-
sociation with the transcription complex, a fact that was
substantiated with the direct evaluation of Nrd1
occupancy by ChIP experiments. Indeed, Nrd1 recruit-
ment across two representative genes, PMA1 and PGK1
(Figure 8 and Supplementary Figure S2), is shown to
increase dramatically in the presence of Rho expression
and this trend is alleviated by overproduction of
competing suppressors.
What makes the transcription complex so attractive for
Nrd1 association in the presence of Rho helicase/
translocase activity? Co-transcriptional recruitment of
Nrd1 was shown to be predominant at promoter-proximal
regions matching the high level of CTD Ser5 phosphoryl-
ation. This was taken to explain the preferential involve-
ment of Nrd1 complex in termination of short transcripts
such as non-coding RNAs and CUTs (39,40). However, as
detected with our ChIP experiments in the absence of
Rho, recent data indicate that a basal level of Nrd1 asso-
ciation with transcribing RNAP II persists throughout
elongation, apparently due to the persistence of a certain
level of phosphorylated Ser5 residues (42,43). Moreover,
this basal level of Nrd1 recruitment was shown to increase
substantially and provoke termination at a site located
>1.5kb from a promoter when poly(A)-dependent
Nucleic Acids Research,2011, Vol.39, No. 7 2817termination is impaired (43). These results along with
others suggest that the choice between the two termination
modes is governed by a continuous competition between
the two termination machineries for recruitment by the
transcription complex, with the CID-containing proteins
Nrd1 and Pcf11 being the prominent components of the
two machineries (39,40).
We propose that a similar competition process, but in a
biased way, is taking place for the recognition and target-
ing of Rho-induced aberrant transcripts. In effect,
stripping of nascent transcripts from processing and
packaging factors by Rho action should uncover speciﬁc
RNA-binding sites promoting preferential recruitment of
Nrd1 (Figure 9). For instance, this is well illustrated by
our results with the CID-defective pcf11–13 strain in
which the Rho-induced defect is aggravated, reﬂecting
the unbalance in the competition between mutant Pcf11–
13 and Nrd1. Conversely, the competition is
counterbalanced at the expense of Nrd1 in the case of
Pcf11 overproduction or in mutant strains with defective
Nrd1 (nrd1D1–151 or nrd1–102 alleles). Work in progress
in our laboratory indicates that a similar competition
process is obtained by overexpression of other
CTD-interacting proteins. In addition to Pcf11, Rna14
which is known to interact with the CTD was found as
a dosage suppressor of the Rho-induced defect in our
previous screen (44). In contrast, overexpression of the
two other members of the CF1A complex, Rna15 and
Clp1, for which CTD binding has not been found in
two-hybrid experiments (31), did not confer any suppress-
ing phenotype. A similar correlation between known
CTD binding activity and dosage suppression of the
Rho-induced defect is also found for some components
of the CPF complex.
In this biased competition model, Nrd1 might be weakly
anchored to the transcription complex through interaction
of its CID with the CTD, then the interaction is further
stabilized by binding to speciﬁc RNA segments uncovered
by Rho action. In this regard, our results suggest that
Nab3 association with Nrd1 plays a key role in the stabil-
ization process. First, a rescue of Rho-induced aberrant
transcripts with accompanying relief of growth defect is
observed in a strain with a defect in Nab3 RNA-binding
domain (nab3–11 allele). Second, the dominant-negative
effect induced by overexpression of Nrd1 deletion
mutants is more robust when the protein fragments
include the Nab3-interacting domain in addition to the
CID. We note that the transcripts derived from the two
representative genes studied in this work (PMA1 and
PGK) contain much more Nab3 (UCUU) than Nrd1
(GUAA/G) binding sites (27 and 15 compared to 2 and
5, respectively) which should expend the opportunity for
RNA stabilizing interactions and thus the recognition of
a wide range of aberrant transcripts. These consider-
ations are consistent with previous reports in which the
formation of Nrd1–Nab3 heterodimer was shown to
be the primary speciﬁcity determinant for transcription
termination of small non-coding RNAs and CUTs.
For instance, a CUT terminator containing only Nab3
binding sites functions efﬁciently in wild-type cells
but does not function in the nab3–11 mutant strain,
indicating that the Nab3 interaction with the transcript
is sufﬁcient to stabilize the recruitment of the heterodimer
(36,48).
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Figure 9. Model illustrating the Nrd1-mediated recognition and degradation of Rho-induced aberrant transcripts. (A) Normal conditions of mRNP
biogenesis. Nrd1 complex is recruited to the transcription complex at early elongation then is outcompeted by the deposition of mRNA processing
and binding proteins as RNAP II travels further downstream. (B) Rho-induced defective mRNP biogenesis. Rho loading and tracking along nascent
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and association of nuclear RNA degradation machinery represented by Rrp6. Upon transcription completion, the aberrant transcript would be
degraded by the exoribonuclease activity of Rrp6 either alone or in association with the core exosome.
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physical interactions between the exosome–TRAMP
complex and Nrd1 (22). This was taken to suggest that
co-transcriptional recruitment of Nrd1 could help to
tether the exosome-dependent degradation machinery to
the transcription complex. Our ChIP results provide a
direct evidence for such suggestion by showing a correl-
ation between the Rho-induced large increase of Nrd1 re-
cruitment and the enrichment of nuclear-speciﬁc exosome
component Rrp6 across the PMA1 gene. A general belief
for nuclear mRNA surveillance is that Rrp6
exoribonuclease activity acts in concert with the core
exosome through physical interactions. However, our
ChIP experiments using tagged Rrp4 and Rrp41 did not
reveal any association of these core exosomal subunits
with the tethered surveillance machinery. This could be
due to the fact that the core exosome does not have
close contacts with RNA and DNA within the transcrip-
tion complex and thus is less efﬁciently cross-linked to
chromatin. A second possibility could be that the inter-
actions of the core exosome with Nrd1 and Rrp6 are
rather weak, which may explain the fact that in the
Nrd1 co-immunoprecipitates, the core exosome compo-
nents were signiﬁcantly underrepresented as compared
to Nab3, Rrp6 or the TRAMP component Air2 (22). A
third possibility, which we favor, could be that
co-transcriptional recruitment and RNA binding of
Nrd1 followed by Rrp6 tethering constitutes the ﬁrst
step at which a defect is detected and the transcript
is labeled as aberrant. Subsequently, the labeled tran-
script would be prevented from export then directed
for destruction by facilitating a close coupling of Rrp6
with the core exosome scaffold (Figure 9). This second
step is probably achieved upon transcription comple-
tion since exoribonuclease degradation by the exosome–
Rrp6 complex requires exposed RNA 30-end. However,
an alternative scenario of this last model could be
that Rrp6 exoribonuclease activity acts independently
from core exosome to degrade aberrant transcripts.
This scenario is supported by recent ﬁndings in which
Rrp6 was found to carry out some of its exoribonuclease
functions without physical association with the core
exosome and to be stimulated by the TRAMP complex
(52,53). Whatever the precise mechanism, this Nrd1–
Rrp6-tagging model could explain how a general quality
control system recognizes various aberrancies arising at
different steps of mRNP biogenesis such as splicing, ter-
mination and 30-end formation or assembly and export,
then directs the defective molecules to the same outcome,
destruction. In this regard, although our experimental
approach uses an artiﬁcial system in which mRNPs are
actively depleted from processing and packaging factors
by Rho action, it gives a hint of what is likely to happen
under naturally occurring circumstances that result in de-
fective mRNP formation. However, it should be
emphasized that the existence of alternative pathways
for the mRNA surveillance mechanism cannot be
excluded, especially in the case of transcripts in which
Nrd1 and Nab3 binding sites are poorly represented or
absent.
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